Company intelligence / Profile preview

Lannett

Trevose, Pennsylvania, United States

Ownership: Public · LCI
Employees: ~1100
Development stage: Other

Overview

Lannett has over 100 marketed generic pharmaceutical products in the US, including newly approved products such as mycophenolate mofetil for oral suspension and a portfolio of both high-value and traditional generics in solid, liquid, and semi-solid forms, with additional ANDAs pending or in late-stage development[1][2][4][9].

Therapeutic areas: ImmunologyRheumatologyPsychiatryInfectious DiseasesCardiovascularOtherNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Jerome Stevens Pharmaceuticals (levothyroxine distribution, now expired)[2]Endo International (acquisition of product portfolio)[6][8]Societal CDMO Gainesville LLC (distribution agreement for verapamil; recently terminated)[2]

Financials

Market cap: $7.4M
Total revenue: $80.5M
Enterprise value: $600.5M

Beyond the preview

Go deeper on Lannett.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lannett.

Explore the full profile